title: Preoperative immunoglobulin treatment in patients with Werlhof's disease undergoing cardiac operation.
abstract: BACKGROUND
  Patients with Werlhof's disease and undergoing a cardiac surgical procedure with cardiopulmonary bypass are at increased risk for bleeding complications. We report the usefulness of preoperative immunoglobulin treatment in selected patients.
  
  
  METHODS
  Between May 1995 and July 1998, 10 patients with Werlhof's disease underwent a cardiac surgical procedure with cardiopulmonary bypass in our department. Five patients with mean platelet counts of less than 80x10(9)/L received immunoglobulin therapy preoperatively (group 1). The other 5 patients with mean platelet counts higher than 80x10(9)/L were not so treated (group 2).
  
  
  RESULTS
  In group 1, mean platelet count increased from 54x10(9)/L 5 days before operation to 112x10(9)/L after immunoglobulin treatment (p = 0.018) and did not fall to less than 60x10(9)/L postoperatively. Patients in group 1 received 16 units of packed red blood cells and 5 units of platelet concentrate. Patients in group 2 required 24 units of packed red blood cells, 5 units of platelet concentrate, and 23 units of fresh frozen plasma. Only 1 patient (group 2) had a surgical bleeding complication that required reexploration. Mean drainage loss was 1,100 mL in group 1 and 1,210 mL in group 2.
  
  
  CONCLUSIONS
  Our data demonstrate that immunoglobulin treatment of patients with Werlhof's disease and mean platelet counts of less than 80x10(9)/L significantly augments platelet counts preoperatively. It may be useful in selected patients.
authors.affiliation: Department of Cardiothoracic Surgery, Westphalian Wilhelms-University, Münster, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Christiansen
authors.forename: C
authors.initials: C
authors.lastname: Schmid
authors.forename: K
authors.initials: K
authors.lastname: Redmann
authors.forename: U R
authors.initials: UR
authors.lastname: Jahn
authors.forename: J
authors.initials: J
authors.lastname: Stypmann
authors.forename: H H
authors.initials: HH
authors.lastname: Scheld
authors.forename: D
authors.initials: D
authors.lastname: Hammel
mesh_terms: D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical / Q000517:prevention & control; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D003327:Coronary Disease / Q000601:surgery; D017707:Erythrocyte Transfusion; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010949:Plasma; D010976:Platelet Count; D017713:Platelet Transfusion; D019106:Postoperative Hemorrhage / Q000209:etiology; D011300:Preoperative Care; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000628:therapy*; D012086:Reoperation; D012307:Risk Factors; D015996:Survival Rate; D013921:Thrombocytopenia / Q000097:blood
chemical_list: D016756:Immunoglobulins, Intravenous